These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 26691221)
1. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. Vogel TJ; Jeon C; Karlan B; Walsh C Gynecol Oncol; 2016 Feb; 140(2):285-8. PubMed ID: 26691221 [TBL] [Abstract][Full Text] [Related]
2. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Vogel TJ; Goodman MT; Li AJ; Jeon CY Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017 [TBL] [Abstract][Full Text] [Related]
3. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer. Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307 [TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Champer M; Huang Y; Hou JY; Tergas AI; Burke WM; Hillyer GC; Ananth CV; Neugut AI; Hershman DL; Wright JD Gynecol Oncol; 2018 Jan; 148(1):19-27. PubMed ID: 29153542 [TBL] [Abstract][Full Text] [Related]
6. Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study. Doll KM; Pinheiro LC; Reeve BB Gynecol Oncol; 2017 Feb; 144(2):348-353. PubMed ID: 27988047 [TBL] [Abstract][Full Text] [Related]
7. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490 [TBL] [Abstract][Full Text] [Related]
8. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659 [TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer outcomes: Predictors of early death. Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531 [TBL] [Abstract][Full Text] [Related]
10. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Joseph N; Clark RM; Dizon DS; Lee MS; Goodman A; Boruta D; Schorge JO; Del Carmen MG; Growdon WB Gynecol Oncol; 2015 Jun; 137(3):401-5. PubMed ID: 25839911 [TBL] [Abstract][Full Text] [Related]
11. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105 [TBL] [Abstract][Full Text] [Related]
12. Racial disparities in the treatment of advanced epithelial ovarian cancer. Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782 [TBL] [Abstract][Full Text] [Related]
13. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population. Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA Gynecol Oncol; 2011 Dec; 123(3):461-6. PubMed ID: 21945309 [TBL] [Abstract][Full Text] [Related]
15. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556 [TBL] [Abstract][Full Text] [Related]
16. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889 [TBL] [Abstract][Full Text] [Related]
17. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. Fairfield KM; Murray K; Lucas FL; Wierman HR; Earle CC; Trimble EL; Small L; Warren JL J Clin Oncol; 2011 Oct; 29(29):3921-6. PubMed ID: 21911719 [TBL] [Abstract][Full Text] [Related]
18. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697 [TBL] [Abstract][Full Text] [Related]
19. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study. Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Miao Y; Li S; Yan Q; Li B; Feng Y Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]